Cell-El, Using AI & Biomarkers to Improve Autism Care
A simple blood test, empowering results
Cell-El Therapeutics Ltd. created algorithms using AI technology to analyze blood-based protein biomarkers (proteomics). Cell-El’s test offers objective diagnostic support for children from age 2 with suspected Autism Spectrum Disorder (ASD).
Cell-El’s test identifies biological patterns of children with ASD differentiating them from their typically developing (TD) peers. The test is being evaluated as a precision medicine tool for guiding immune- and cell-based therapies in ASD.
MISSION
Cell-El’s mission is to identify ASD in infancy and to advance AI‑based precision medicine. This approach may enable personalized therapeutic treatment options and improve outcomes.
PROTEOMICS
PARTICIPATE
With the goal to reduce the diagnostic age to benefit children with ASD, Cell-El’s ongoing infant study identifies proteomic markers in high-risk infants aged 10-18 months.
The Cell-El Multi-Center Study
In a multi-center study, Cell-El examined the biomarkers of more than 400 children aged 2–12 years. AI tools were used to distinguish children with ASD from their typically developing peers.
Building on these findings, Cell-El’s study has now expanded to include high-risk infants (with a sibling diagnosed with ASD) from 10 months of age and their mothers. Cell-El’s technology is also being used to monitor children aged 2-18 years with ASD who are undergoing stem-cell treatment. The study has approvals from the Helsinki ethics committees and the Israeli Ministry of Health.
Click here to read more about our study
- Sign Up
We look forward to your participation in the Cell-El screening study. Please read the information below regarding the inclusion and exclusion criteria for the following cohorts: 1. Infants and their mothers and 2. Children pre and post Stem Cell Therapy (SCT). Then please fill out the appropriate form. Please note: At this time we are only recruiting participants residing in Israel.
- Cohorts of infants and their mothers: Mothers of high-risk infants and infants aged 10-18 months not diagnosed with ASD, but with a sibling diagnosed with ASD according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV (299.00) or DSM-V (299.00) or
- Cohorts of children pre and post SCT: Male and female children age 2-18 years old diagnosed with autism spectrum disorder (ASD) according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV (299.00) or DSM-V (299.00) undergoing stem cell therapy.
- For all cohorts: Informed consent signed by the parents
For all cohorts:
- Child and/or mother completed treatment with systemic steroids or immune suppressants less than 4 weeks before the screening visit
- Child and/or mother diagnosed with severe infectious diseases or sepsis over the last 6 months
- Child and/or mother with hematological or malignant disorder
- Child with ASD treated for a severe convulsive disorder
For children in the SCT cohort:
- No new planned immune-modulating treatment (other than SCT) for at least 6 months before or after planned stem cell transplantation date.
If you are a parent of a child diagnosed with ASD, please click here to fill out the form.
- More Information
Read our research and peer reviewed articles. For any additional questions, please fill out the form below
- Autism Spectrum Disorder Diagnosis using a New Panel of Immune – and Inflammatory – Related Serum Biomarkers: A Case-Control Multicenter Study, Frontiers in Pediatrics
- Autism Spectrum Disorders (ASD) – Searching For the Biological Basis For behavioral Symptoms And new Therapeutic Targets, Frontiers in Neuroscience and Frontiers in Pediatrics
- Immunological and autoimmune considerations of Autism Spectrum Disorders, Journal of Autoimmunity
To receive more information, please fill out the form below.
